Industry, government, and academic panel discussion on multiple comparisons in a "real" phase three clinical trial.
A Food and Drug Administration (FDA)/Industry/Academic Panel Discussion on multiplicity aspects of a real Phase III clinical trial was held at the Third International Conference on Multiple Comparisons, August 6, 2002, in Bethesda, Maryland. The goal was to develop some consensus among industry, government, and academic statisticians concerning requirements and methods for multiplicity management in typical clinical trials. The session was tape-recorded; this article mostly comes from an edited transcript.
Bauer
Peter
P
University of Vienna, Vienna, Austria. peter.bauer@univie.ac.at
Chi
George
G
Geller
Nancy
N
Gould
A Lawrence
AL
Jordan
David
D
Mohanty
Surya
S
O'Neill
Robert
R
Westfall
Peter H
PH
D017326:Clinical Trials, Phase III as Topic / Q000379:methods*; D004345:Drug Industry / Q000379:methods* / Q000592:standards; D006801:Humans; D018579:Patient Selection; D014481:United States; D014486:United States Food and Drug Administration / Q000592:standards